{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:09:28Z","timestamp":1772730568983,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.diabres.2011.04.010","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T23:24:44Z","timestamp":1306452284000},"page":"187-197","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain"],"prefix":"10.1016","volume":"93","author":[{"given":"Lynn R.","family":"Webster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Peppin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick T.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey K.","family":"Tobias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertrui F.","family":"Vanhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.diabres.2011.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 5","key":"10.1016\/j.diabres.2011.04.010_bib0010","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0885-3924(03)00065-4","article-title":"Unmet needs in the management of neuropathic pain","volume":"25","author":"Harden","year":"2003","journal-title":"J Pain Symptom Manage"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2011.04.010_bib0015","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jpain.2007.10.008","article-title":"Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00002508-200211000-00002","article-title":"Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy","volume":"18","author":"Schmader","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0025","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bmj.326.7392.748","article-title":"Treatment of herpes zoster and postherpetic neuralgia","volume":"326","author":"Johnson","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.diabres.2011.04.010_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2011.04.010_bib0035","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1111\/j.1526-4637.2006.00179.x","article-title":"Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review","volume":"8","author":"Barrett","year":"2007","journal-title":"Pain Med"},{"key":"10.1016\/j.diabres.2011.04.010_bib0040","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","article-title":"Diabetic somatic neuropathies","volume":"27","author":"Boulton","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2011.04.010_bib0045","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic neuropathies: a statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2011.04.010_bib0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1464-5491.2003.00852.x","article-title":"The pathogenesis and management of painful diabetic neuropathy: a review","volume":"20","author":"Spruce","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2011.04.010_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00400697","article-title":"A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population","volume":"36","author":"Young","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2011.04.010_bib0060","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1212\/01.wnl.0000218303.48113.5d","article-title":"HIV neuropathy natural history cohort study: assessment measures and risk factors","volume":"66","author":"Simpson","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.diabres.2011.04.010_bib0065","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2165\/00003495-200059060-00005","article-title":"HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment","volume":"59","author":"Wulff","year":"2000","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.diabres.2011.04.010_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.diabres.2011.04.010_bib0075","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1468-1331.2007.01916.x","article-title":"EFNS guidelines on neurostimulation therapy for neuropathic pain","volume":"14","author":"Cruccu","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.diabres.2011.04.010_bib0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2007\/730785","article-title":"Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society","volume":"12","author":"Moulin","year":"2007","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.diabres.2011.04.010_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1533-2500.2006.00055.x","article-title":"Pharmacotherapy for neuropathic pain","volume":"6","author":"Jackson","year":"2006","journal-title":"Pain Pract"},{"key":"10.1016\/j.diabres.2011.04.010_bib0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0304-3959(99)00154-2","article-title":"Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action","volume":"83","author":"Sindrup","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-7-11","article-title":"Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy","volume":"7","author":"Facer","year":"2007","journal-title":"BMC Neurol"},{"key":"10.1016\/j.diabres.2011.04.010_bib0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2559.2007.02851.x","article-title":"Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human patients","volume":"51","author":"Wilder-Smith","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.diabres.2011.04.010_bib0110","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1432-1033.2004.04082.x","article-title":"Biochemical pharmacology of the vanilloid receptor TRPV1. An update","volume":"271","author":"Cortright","year":"2004","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.diabres.2011.04.010_bib0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0031-6997(24)01403-0","article-title":"Vanilloid (capsaicin) receptors and mechanisms","volume":"51","author":"Szallasi","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.diabres.2011.04.010_bib0120","series-title":"Vanilloid receptor TRPV1 in drug discovery: medicinal chemistry, biology, and therapeutic potential for chronic pain and pathological disorders","first-page":"325","article-title":"TRPV1 agonist approaches for pain management","author":"Bley","year":"2010"},{"key":"10.1016\/j.diabres.2011.04.010_bib0125","first-page":"CD007393","article-title":"Topical capsaicin for chronic neuropathic pain in adults","volume":"4","author":"Derry","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"7446","key":"10.1016\/j.diabres.2011.04.010_bib0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/bmj.38042.506748.EE","article-title":"Systematic review of topical capsaicin for the treatment of chronic pain","volume":"328","author":"Mason","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.diabres.2011.04.010_bib0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0885-3924(99)00139-6","article-title":"Topical capsaicin in the management of HIV-associated peripheral neuropathy","volume":"19","author":"Paice","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1016\/j.diabres.2011.04.010_bib0140","first-page":"702","article-title":"NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain","volume":"10","author":"Noto","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.diabres.2011.04.010_bib0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpainsymman.2007.04.015","article-title":"An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy","volume":"35","author":"Simpson","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.diabres.2011.04.010_bib0150","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1212\/01.wnl.0000314647.35825.9c","article-title":"A trial of a high-concentration capsaicin patch for the treatment of painful HIV neuropathy","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.diabres.2011.04.010_bib0155","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.diabres.2011.04.010_bib0160","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1526-4637.2009.00793.x","article-title":"NGX-4010. A high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension","volume":"11","author":"Backonja","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.diabres.2011.04.010_bib0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1526-4637.2010.01004.x","article-title":"A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia","volume":"12","author":"Irving","year":"2011","journal-title":"Pain Med"},{"key":"10.1016\/j.diabres.2011.04.010_bib0170","first-page":"323","article-title":"Tolerability of NGX-4010 in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain","volume":"11","author":"Webster","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.diabres.2011.04.010_bib0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0180","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products. Washington, DC: US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research; 1999. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/990236Gd.pdf#search=%22HillTop%20Research%2C%20Inc.%20dermal%20irritation%22 [accessed 15.09.10]."},{"issue":"12 Suppl 1","key":"10.1016\/j.diabres.2011.04.010_bib0185","first-page":"A346","article-title":"Treatment of painful HIV-associated distal sensory polyneuropathy (DSP) with a high-concentration capsaicin dermal patch (NGX-4010): report of a 52-week study","volume":"68","author":"Simpson","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.diabres.2011.04.010_bib0190","first-page":"S51","article-title":"Duration of treatment response to NGX-4010, a high-concentration capsaicin patch, in patients with postherpetic neuralgia","volume":"11","author":"Webster","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0195","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jpainsymman.2009.11.316","article-title":"Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain","volume":"39","author":"Simpson","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.diabres.2011.04.010_bib0200","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2004.07.017","article-title":"Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch","volume":"111","author":"Malmberg","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.diabres.2011.04.010_bib0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jpain.2009.09.019","article-title":"A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers","volume":"11","author":"Kennedy","year":"2010","journal-title":"J Pain"},{"issue":"11","key":"10.1016\/j.diabres.2011.04.010_bib0210","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1001\/archinte.1991.00400110079017","article-title":"Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study","volume":"151","author":"The Capsaicin Study Group","year":"1991","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2011.04.010_bib0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/diacare.15.1.8","article-title":"Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up","volume":"15","author":"Tandan","year":"1992","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2011.04.010_bib0220","first-page":"111","article-title":"A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy","volume":"12","author":"Biesbroeck","year":"1995","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.diabres.2011.04.010_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s005920200005","article-title":"The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy","volume":"39","author":"Forst","year":"2002","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.diabres.2011.04.010_bib0230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2796.2000.00749.x","article-title":"Direct medical costs for patients with type 2 diabetes in Sweden","volume":"248","author":"Henriksson","year":"2000","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.diabres.2011.04.010_bib0235","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1534734609336948","article-title":"Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice","volume":"8","author":"Ndip","year":"2009","journal-title":"Int J Low Extrem Wounds"},{"issue":"7","key":"10.1016\/j.diabres.2011.04.010_bib0240","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2337\/diacare.21.7.1071","article-title":"Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration","volume":"21","author":"Abbott","year":"1998","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711001914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711001914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T21:29:28Z","timestamp":1741210168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822711001914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0168822711001914"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2011.04.010","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}